Related Experiment Video
Updated: Aug 8, 2026
02:09
Application of Laparoscopic Partial Splenectomy with Total Blood Flow Occlusion in Benign Splenic Lesions
Published on: December 20, 2024
Subtotal splenectomy for Gaucher's disease: a follow-up study
L Morgenstern1, R Verham, I Weinstein
1Department of Surgery, Cedars-Sinai Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.
The American Surgeon
|December 1, 1993
Summary
Partial splenectomy for Gaucher's disease leads to splenic regrowth and hypersplenism recurrence. Enzyme replacement therapy (Ceredase) offers a promising new treatment option for Gaucher's disease patients.
Area of Science:
- Biochemistry
- Genetics
- Internal Medicine
Background:
- Gaucher's disease is a lysosomal storage disorder.
- Partial splenectomy has been used to manage hypersplenism in Gaucher's disease.
- Understanding long-term outcomes of splenectomy is crucial for patient management.
Observation:
- Three Gaucher's disease patients who underwent partial splenectomy were followed for 3 to 8.5 years.
- All patients experienced significant regrowth of the splenic remnant.
- Recurrence of hypersplenism was observed in all patients.
Findings:
- Partial splenectomy in Gaucher's disease is associated with splenic regrowth.
- Hypersplenism frequently recurs after partial splenectomy for Gaucher's disease.
- A review of existing literature supports these findings.
Implications:
- Partial splenectomy may not provide a permanent solution for hypersplenism in Gaucher's disease.
- Enzyme replacement therapy (Ceredase) presents a promising alternative treatment.
- Further research into long-term Gaucher's disease management strategies is warranted.
